Mesothelioma Stratified Therapy (MiST): A stratified multi-arm phase II clinical trial to enable accelerated evaluation of targeted therapies for relapsed malignant mesothelioma.

niversity of Leicester0 个研究点目标入组 200 人开始时间: 2018年10月1日最近更新: 2022年9月12日

适应症

试验速览

2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33515503/ MiST1 (added 28/06/2022) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35157829/ MiST2 (added 28/06/2022)

•Pre-screening:
•1. Histologically confirmed MM with an available biopsy for research purposes
•2. Aged 18 years or older
•3. Expected survival of =12 weeks or greater
•4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
•5. CT scan of chest and abdomen (and pelvis if applicable) confirming disease progression
•6. Received at least one prior line of therapy to include a platinum doublet first-line chemotherapy (within or outside of another clinical trial)
•7. Willing to consent for molecular screening of archived tumour block (PIS1 & CF1)
•Each individual MiST drug protocol contains the eligibility criteria specific to the treatment allocated to the patient and these are yet to be finalised.

•Pre-screening:
•1. Diagnosis of a second malignancy except prostate or cervical cancer in remission, or a diagnosis of basal cell carcinoma of the skin or superficial bladder cancer
•2. Uncontrolled CNS disease (asymptomatic brain metastases are allowed if previously treated with radiotherapy >28 days prior to starting the investigational agent)
•3. New York Heart Association Class II or greater congestive heart failure
•4. Severe hepatic insufficiency or severe renal impairment
•5. Requiring long term oxygen therapy.
•6. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial

发起方

niversity of Leicester